Related references
Note: Only part of the references are listed.The loss or absence of minimal residual disease of <0•1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis
Wenbing Duan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1
Byung-Sik Cho et al.
CANCERS (2021)
Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia
Martin Sula et al.
BONE MARROW TRANSPLANTATION (2020)
The clinical mutatome of core binding factor leukemia
Sabrina Opatz et al.
LEUKEMIA (2020)
Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
Jochen Greiner et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Yuichi Ishikawa et al.
BLOOD ADVANCES (2020)
Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBF/MYH11 gene expression
Zhao Xiaosu et al.
ANNALS OF HEMATOLOGY (2019)
Different prognostic effects of core-binding factor positive AML with Korean AML registry data
Ho-Jin Shin et al.
ANNALS OF HEMATOLOGY (2019)
Cellular therapy for acute myeloid Leukemia - Current status and future prospects
Panupong Hansrivijit et al.
BLOOD REVIEWS (2019)
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2019)
Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapseafter allogeneic haematopoietic cell transplantation inadults with inv(16) acute myeloid leukaemia
Fei-Fei Tang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Peter Paschka et al.
LEUKEMIA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
Jae-Ho Yoon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Nicolas Duployez et al.
BLOOD (2016)
The genomic landscape of core-binding factor acute myeloid leukemias
Zachary J. Faber et al.
NATURE GENETICS (2016)
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia
W. Jang et al.
BLOOD CANCER JOURNAL (2016)
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Wenlan Chen et al.
PLOS ONE (2016)
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
Federico Mosna et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy
Ya-Zhen Qin et al.
LEUKEMIA & LYMPHOMA (2015)
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
Yu Wang et al.
BLOOD (2014)
Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation
J-H Yoon et al.
BONE MARROW TRANSPLANTATION (2014)
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement
Hee-Jin Kim et al.
ANNALS OF HEMATOLOGY (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Yachiyo Kuwatsuka et al.
BLOOD (2009)
Autologous Stem Cell Transplantation with PCR-Negative Graft Would Be Associated with a Favorable Outcome in Core-Binding Factor Acute Myeloid Leukemia
Hideki Nakasone et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation
Norbert-Claude Gorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N. Boissel et al.
LEUKEMIA (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
